Opko Health (OPK) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Opko Health (OPK) PT Trimmed at Jefferies Post Q2, 'Buy' Maintained
August 13, 2014 7:54 AM EDTJefferies analyst Eun K. Yang, Ph.D trimmed his price target on Buy-rated Opko Health (NYSE: OPK) to $10.50 (from $11.00) following Q2 results but maintained a Buy rating.
Yang commented, "Narrower 2Q14 net loss of $25.5M (vs. ours of $31.8M) primarily on... More
OPKO Health (OPK) Reports Positive Top Line Results from Rayaldee Phase 3 Trial
August 11, 2014 4:31 PM EDTOPKO Health, Inc. (NYSE: OPK), announced successful top-line results from the first pivotal phase 3 trial of Rayaldee. This trial is one of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldee as a new treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D... More
OPKO Health (OPK) Continues Higher Following Rayaldee IND Submission
August 8, 2014 3:48 PM EDTOPKO Health (NYSE: OPK) is looking to close higher for the fifth-straight session today, making a strong move back above the $9.25 in the process.
On Thursday afternoon, OPKO... More
OPKO Health (OPK) Submits IND for Rayaldee
August 7, 2014 3:49 PM EDTOPKO Health, Inc. (NYSE: OPK), announced the submission of an Investigational New Drug (IND) Application to the United States (U.S.) Food and Drug Administration (FDA) under which Rayaldee will begin clinical evaluation as an adjunctive therapy for the prevention of skeletal-related events (SREs) in patients with bone metastases... More
